Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SeaStar Medical Holding Corporation (Nasdaq: ICU) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings give investors detailed information about SeaStar Medical’s commercial-stage healthcare business built around its Selective Cytopheretic Device (SCD) therapy and QUELIMMUNE (SCD-PED) product for pediatric acute kidney injury (AKI).
Through Form 8-K current reports, SeaStar Medical discloses material events such as the recommendation of an independent Data Safety Monitoring Review Board to continue the NEUTRALIZE-AKI pivotal trial with zero device-related safety issues, changes in executive leadership, and corporate actions like the approval and implementation of a 1-for-10 reverse stock split to adjust the company’s share structure while maintaining its Nasdaq listing. These filings also describe adjustments to clinical trial enrollment targets and other operational updates.
The company’s DEF 14A proxy statements provide details on matters submitted to stockholders, including proposals related to reverse stock splits and authorized share counts. They outline voting procedures, meeting logistics, and the rationale behind capital structure decisions. Together with other periodic and transactional filings, these documents help explain how SeaStar Medical manages its equity, governance, and financing as it advances SCD-based therapies.
On Stock Titan, SeaStar Medical’s filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the key points in complex filings, helping readers quickly understand topics such as trial-related disclosures, compensation arrangements for executives, and the impact of corporate actions on ICU common stock and ICUCW warrants. Users can also review filings that reference the company’s Breakthrough Device Designations, Humanitarian Device Exemption framework for QUELIMMUNE, and pivotal trial plans, gaining a structured view of how regulatory and clinical developments intersect with SeaStar Medical’s capital markets activity.
SeaStar Medical Holding Corp received an updated ownership report from investors Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of December 31, 2025, they report beneficial ownership of 3,980,665 shares of common stock, equal to 9.99% of the class.
The position is entirely through six warrants held by Intracoastal. Three warrants are counted, while three additional warrants are contractually blocked from exercise above 9.99% or 4.99% ownership caps. Without these blocker provisions, their beneficial ownership would be 5,342,845 shares. The group states the holdings are not for changing or influencing control of SeaStar Medical.
SeaStar Medical Holding Corp director Kenneth Van Heel reported receiving a grant of restricted stock units (RSUs) under the company’s equity program. On February 6, 2026, he acquired 3,000 shares of common stock at a price of $0 as an award.
According to the filing, these RSUs will vest in full on February 6, 2027, meaning the shares become fully owned on that date if vesting conditions are met. After this grant, Van Heel beneficially owns 7,940 shares of SeaStar Medical common stock directly.
SeaStar Medical Holding Corp director John Neuman reported a stock-based award. On February 6, 2026, he received 3,000 shares of common stock at a stated price of $0, reported as an acquired transaction.
After this grant, Neuman beneficially owns 12,200 shares of SeaStar Medical common stock in direct form. The filing notes that the 3,000-share award represents restricted stock units (RSUs) that will vest in full on February 6, 2027.
SeaStar Medical Holding Corp director Vincent Bernadette N reported receiving 3,000 shares of common stock on February 6, 2026 under transaction code A, indicating an acquisition. The filing notes this represents a restricted stock unit (RSU) award that will vest in full on February 6, 2027. The shares were acquired at a stated price of $0 per share, leaving the director with 4,200 shares of beneficially owned common stock held directly after the grant.
SeaStar Medical Holding Corp director equity grant: Director Jennifer A. Baird received an award of 3,000 shares of common stock on February 6, 2026, reported at a price of $0 per share. After this grant, she beneficially owns 6,620 shares of the company’s common stock in direct ownership.
The 3,000-share award is structured as restricted stock units (RSUs) that will vest in full on February 6, 2027, meaning the shares are subject to a one-year service-based vesting period before becoming fully owned and freely transferable, subject to any company trading policies.
SeaStar Medical Holding Corp executive Towne Bradford K reported receiving 7,500 shares of common stock as a stock-based award. The shares, reported at a price of $0 per share, increased the executive's directly held stake to 9,050 shares.
The award is in the form of restricted stock units that vest in three equal installments on the first, second and third anniversaries of February 6, 2026. Towne Bradford K serves as the company's Principal Accounting Officer.
SeaStar Medical Holding Corp’s Chief Medical Officer Kevin Chung reported receiving 15,000 shares of common stock as a restricted stock unit (RSU) award on February 6, 2026. The RSUs vest in equal installments on the first, second, and third anniversaries of that date. After this grant, Chung beneficially owned 20,819 shares directly.
SeaStar Medical Holding Corp disclosed that its Chief Executive Officer, Eric Schlorff, received an award of 30,000 shares of common stock in the form of restricted stock units on February 6, 2026, at a grant price of $0 per share.
The RSU award vests in three equal installments on the first, second and third anniversaries of February 6, 2026. Following this grant, Schlorff beneficially owned 39,852 shares of SeaStar Medical common stock, held directly.
SeaStar Medical Holding Corporation reported that it has regained compliance with Nasdaq’s minimum bid price requirement. On January 20, 2026, the company received confirmation from the Nasdaq Office of General Counsel that it once again meets the $1.00 minimum bid price standard set by Nasdaq Listing Rule 5550(a)(2). This means SeaStar Medical’s common stock and warrants continue to qualify for listing on The Nasdaq Stock Market, removing the immediate risk that its shares could be delisted solely for not meeting the bid price rule.
SeaStar Medical Holding Corporation is implementing a 1-for-10 reverse stock split of its common stock, approved at a special shareholder meeting and effective as of 12:01 a.m. Eastern on January 2, 2026. Every 10 existing shares will be combined into one new share, with no fractional shares issued; any fractional positions will be rounded up to the next whole share. All outstanding stock options and warrants will be proportionally adjusted, and the stock will continue trading on the Nasdaq Capital Market under the symbol ICU on a split-adjusted basis starting January 2, 2026. Immediately after the split, there will be approximately 3.8 million shares of common stock outstanding. Shareholders also approved reducing authorized common shares by 25,000,000 to a total of 425,000,000.